Fundraising Fox
Ten63 Therapeutics
Durham, US · Founded 2019 · Delaware corporation · 33 employees on LinkedIn · 12 known investors
Find your way into Ten63 Therapeutics
Sign up to see every warm intro you have to Ten63 Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ten63 Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.
Founders & leadership
Ten63 Therapeutics was founded in 2019 by Mark A. Hallen.
Investors · 12
How we know: Cape Fear BioCapital's portfolio page · Not right? Tell us
How we know: finance.yahoo.com · Not right? Tell us
How we know: a partner's Signal profile · finance.yahoo.com · the VCSheet dataset · Not right? Tell us
How we know: finance.yahoo.com · open dataset · 5k.vc investor directory · sosv.com · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: finance.yahoo.com · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · finance.yahoo.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$18M disclosed across 2 of 3 rounds · 2021–2026
- $15.9MSeries AMay 2023 · 2 sources
Hatteras Venture Partners (lead), Alexandria Venture Investments, Draper Associates, Morpheus Ventures, SOSV, the Sigma Group
Source ↗
▶$2.1MraisedJan 2021 · 7 investors · OtherRule 506(b)
- Marcel FrenkelExecutive Officer, Director
- Mark A. HallenExecutive Officer, Director
- Damien PettyDirector
- Jia Wei XuDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Companies working in the same space as Ten63 Therapeutics.
In the news
Frequently asked questions
- What does Ten63 Therapeutics do?
- Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.
- Who founded Ten63 Therapeutics?
- Ten63 Therapeutics was founded by Mark A. Hallen in 2019.
- Who are Ten63 Therapeutics's investors?
- Ten63 Therapeutics's investors include Cape Fear BioCapital, DFJ DragonFund, Draper Associates, Duke Capital Partners, Hatteras Venture Partners, SOSV, AbbVie, Alexandria and 3 more.
- How much funding has Ten63 Therapeutics raised?
- Ten63 Therapeutics has disclosed $18M raised across 2 of its 3 known rounds.
- Where is Ten63 Therapeutics headquartered?
- Ten63 Therapeutics is headquartered in Durham, US.